Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
27 févr. 2023 08h31 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written...
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
01 févr. 2023 08h01 HE
|
Agile Therapeutics, Inc.
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 ...
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
26 janv. 2023 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one...
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
09 janv. 2023 07h00 HE
|
Agile Therapeutics, Inc.
Fourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022 Full Year 2022 Factory Sales Expected to Increase Approximately 232% from Full Year 2021 Full...
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
01 déc. 2022 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive...
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
07 nov. 2022 16h05 HE
|
Agile Therapeutics, Inc.
Net Revenue Increased 43% from Second Quarter 2022 Largest Quarter-over-Quarter Increase in Net Revenue Achieved by Agile Non-Retail Channel Twirla Cycles Grew 361% from Second Quarter 2022 ...
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
26 oct. 2022 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after...
Agile Therapeutics Announces Reorganization of Leadership Team
07 oct. 2022 16h25 HE
|
Agile Therapeutics, Inc.
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla® James Tursi, M.D. Resigns from Board of...
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice...
Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11 août 2022 16h05 HE
|
Agile Therapeutics, Inc.
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla® Product Supply...